4.35

7.94% 0.32

After Hours: 4.35

Fulcrum Therapeutics Inc (FULC)

Overview News Price History Option Chain Financials Discussions Forecast

Fulcrum Therapeutics Inc stock is traded at $4.35, with a volume of 2.61M. It is up +7.94% in the last 24 hours and up +45.48% over the past month. Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.

Previous Close:

$4.03

Open:

$3.99

24h Volume:

2.61M

Relative Volume:

2.61

Market Cap:

$234.63M

Revenue:

$2.81M

Net Income/Loss:

$-97.34M

P/E Ratio:

-2.4167

EPS:

-1.8

Net Cash Flow:

$-91.47M

1W Performance:

+9.85%

1M Performance:

+45.48%

6M Performance:

-31.82%

1Y Performance:

-22.60%

1-Day Range:

$3.955

$4.39

1-Week Range:

$3.94

$4.64

52-Week Range:

$2.86

$13.70

Fulcrum Therapeutics Inc Stock (FULC) Company Profile

Name

Fulcrum Therapeutics Inc

Sector

Healthcare (1176)

Industry

Biotechnology (673)

Phone

617-651-8851

Address

26 LANDSDOWNE STREET, CAMBRIDGE, MA

Employee

Twitter

@fulcrumtx

Next Earnings Date

2024-11-05

Latest SEC Filings

FULC's Discussions on Twitter

Compare FULC with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
FULC Fulcrum Therapeutics Inc	4.35	234.63M	2.81M	-97.34M	-91.47M	-1.58
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-13-24	Downgrade	H.C. Wainwright	Buy → Neutral
Sep-12-24	Downgrade	BofA Securities	Neutral → Underperform
Sep-12-24	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Sep-12-24	Downgrade	Leerink Partners	Outperform → Market Perform
Sep-12-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Sep-12-24	Downgrade	Stifel	Buy → Hold
Sep-09-24	Upgrade	BofA Securities	Underperform → Neutral
May-20-24	Initiated	Cantor Fitzgerald	Overweight
Mar-13-24	Initiated	RBC Capital Mkts	Outperform
Sep-25-23	Initiated	Goldman	Neutral
Aug-23-23	Upgrade	H.C. Wainwright	Neutral → Buy
Aug-22-23	Upgrade	Stifel	Hold → Buy
May-04-23	Downgrade	Goldman	Buy → Neutral
Mar-10-23	Downgrade	Credit Suisse	Outperform → Neutral
Mar-10-23	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-09-23	Downgrade	Stifel	Buy → Hold
Feb-28-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Feb-24-23	Downgrade	BofA Securities	Neutral → Underperform
Nov-15-22	Initiated	Goldman	Buy
Mar-08-22	Initiated	Oppenheimer	Outperform
Mar-03-22	Upgrade	BofA Securities	Underperform → Neutral
Aug-11-21	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Apr-26-21	Resumed	Credit Suisse	Outperform
Mar-22-21	Initiated	Credit Suisse	Outperform
Mar-02-21	Initiated	Stifel	Buy
Oct-16-20	Initiated	Piper Sandler	Overweight
Aug-12-20	Downgrade	BofA Securities	Neutral → Underperform
Aug-12-20	Reiterated	H.C. Wainwright	Buy
Aug-12-20	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jun-19-20	Downgrade	BofA/Merrill	Buy → Neutral
Jun-17-20	Initiated	BTIG Research	Buy
Oct-03-19	Initiated	H.C. Wainwright	Buy
Aug-12-19	Initiated	BofA/Merrill	Buy

View All

Fulcrum Therapeutics Inc Stock (FULC) Latest News

Dec 19, 2024

Fulcrum Therapeutics (NASDAQ:FULC) shareholders have endured a 77% loss from investing in the stock three years ago - Yahoo Finance

Dec 19, 2024

Dec 18, 2024

Analysts Set Fulcrum Therapeutics, Inc. (NASDAQ:FULC) PT at $9.33 - Defense World

Dec 18, 2024

Dec 17, 2024

Charles Schwab Investment Management Inc. Acquires 393,202 Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - MarketBeat

Dec 17, 2024

Dec 16, 2024

FULC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Fulcrum Therapeutics, Inc. and Encourages Investors to Contact the Firm! - The Eastern Progress Online

Dec 16, 2024

Fulcrum Therapeutics' SWOT analysis: stock faces headwinds after trial setback - Investing.com

Dec 16, 2024

Dec 15, 2024

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat

Dec 15, 2024

Dec 13, 2024

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Stock Holdings Trimmed by Fmr LLC - MarketBeat

Dec 13, 2024

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Sold by Fmr LLC - Defense World

Dec 13, 2024

Dec 12, 2024

Fulcrum Therapeutics Insider Purchases Yet To Pay Off Regardless Of Recent Strength - Simply Wall St

Dec 12, 2024

Dec 10, 2024

Jacobs Levy Equity Management Inc. Takes $721,000 Position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - MarketBeat

Dec 10, 2024

Dec 06, 2024

BlackRock, Inc. Reduces Stake in Fulcrum Therapeutics Inc. - GuruFocus.com

Dec 06, 2024

Dec 05, 2024

Fulcrum Therapeutics' SWOT analysis: stock faces challenges after trial setback - Investing.com Nigeria

Dec 05, 2024

RA Capital Management L.P. Sells 1,380,605 Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - MarketBeat

Dec 05, 2024

Nov 30, 2024

Braidwell LP Acquires New Stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - MarketBeat

Nov 30, 2024

Connor Clark & Lunn Investment Management Ltd. Makes New $474,000 Investment in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - MarketBeat

Nov 30, 2024

Nov 29, 2024

Fulcrum Therapeutics (FULC) Upgraded to Buy: Here's Why - MSN

Nov 29, 2024

Suvretta Capital Management LLC Sells 1,358,255 Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - MarketBeat

Nov 29, 2024

Nov 27, 2024

Fulcrum Therapeutics to Participate in Upcoming December Conferences - The Manila Times

Nov 27, 2024

Nov 26, 2024

Fulcrum Therapeutics to Present at Three Major Healthcare Conferences in December | FULC Stock News - StockTitan

Nov 26, 2024

Nov 21, 2024

CAMP4 Therapeutics Corporation (CAMP) reports earnings - Quartz

Nov 21, 2024

Nov 20, 2024

Brokerages Set Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Price Target at $9.33 - MarketBeat

Nov 20, 2024

Nov 19, 2024

Facioscapulohumeral Muscular Dystrophy Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Fulcrum Therapeutics, aTyr Pharma, Fulcrum Therapeutics, Hoffmann-La Roche - The Globe and Mail

Nov 19, 2024

Fulcrum Therapeutics stock hits 52-week low at $2.87 By Investing.com - Investing.com Canada

Nov 19, 2024

Simplify Asset Management Inc. Sells 323,518 Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - MarketBeat

Nov 15, 2024

Fulcrum Therapeutics Third Quarter 2024 Earnings: US$0.35 loss per share (vs US$0.39 loss in 3Q 2023) - Yahoo Finance

Nov 15, 2024

Nov 14, 2024